Applicability and Results of Liver Stiffness Measurement and Controlled Attenuation Parameter Using XL Probe for Metabolic-Associated Fatty Liver Disease in Candidates to Bariatric Surgery. A Single-Center Observational Study.

Wan, Tao; Köhn, Nastassja; Kröll, Dino; Berzigotti, Annalisa (2021). Applicability and Results of Liver Stiffness Measurement and Controlled Attenuation Parameter Using XL Probe for Metabolic-Associated Fatty Liver Disease in Candidates to Bariatric Surgery. A Single-Center Observational Study. Obesity surgery, 31(2), pp. 702-711. Springer-Verlag 10.1007/s11695-020-04971-w

[img] Text
Wan2020_Article_ApplicabilityAndResultsOfLiver (1).pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (616kB) | Request a copy

PURPOSE

Patients with morbid obesity are at high risk of liver fibrosis due to metabolic-associated fatty liver disease. Data on liver stiffness measurement (LSM) and controlled attenuation parameter (CAP) by vibration-controlled transient elastography (VCTE, FibroScan®) XL probe for liver fibrosis and steatosis assessment in morbid obesity are needed.

MATERIALS AND METHODS

LSM and CAP were measured in candidates to bariatric surgery at a single center during 12 months. In patients who underwent an intraoperative liver biopsy, we compared LSM and CAP with histology findings. Comorbidities, body mass index, type of surgery, and infections after surgery were collected and analyzed.

RESULTS

Of the eighty-three patients assessed by XL probe, 49 (59%; female in 63%, BMI 42.6 ± 5.1 kg/m2) had a valid LSM and CAP measurement. LSM was 7.0 ± 3.9 kPa and CAP 329 ± 57 dB/m. In the 14 patients undergoing intraoperative liver biopsy, all had steatosis (severe in 50%), 6 (43%) had NASH (NAS ≥ 5), and 4 (29%) showed significant or bridging fibrosis. LSM accurately discriminated between patients with and without significant or severe fibrosis (AUROC 0.833) and CAP well-identified patients with or without ≥S2 steatosis (AUROC 0.896). Nine of 49 patients (18%) tested positive for significant/severe fibrosis by LSM (cut-off 8.9 kPa).

CONCLUSION

Applicability of LSM and CAP by XL probe in patients candidate to bariatric surgery was moderate. However, when technically successful, their reliability to diagnose severe steatosis and fibrosis related to MAFLD was good.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine > Hepatology
04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine > Visceral Surgery
04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Hepatologie
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Hepatologie

UniBE Contributor:

Wan, Tao; Köhn, Olga Gertrud Nastassja; Kröll, Dino and Berzigotti, Annalisa

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0960-8923

Publisher:

Springer-Verlag

Language:

English

Submitter:

Rahel Fuhrer

Date Deposited:

09 Dec 2020 17:13

Last Modified:

02 Feb 2021 01:32

Publisher DOI:

10.1007/s11695-020-04971-w

PubMed ID:

32959331

Uncontrolled Keywords:

Cirrhosis Laparoscopic Roux-en-Y gastric bypass Liver fibrosis Liver steatosis Non-invasive Sleeve gastrectomy

BORIS DOI:

10.7892/boris.148166

URI:

https://boris.unibe.ch/id/eprint/148166

Actions (login required)

Edit item Edit item
Provide Feedback